Printer Friendly

TRADING OF U.S. BIOSCIENCE STOCK SUSPENDED PENDING CONCLUSION OF FDA COMMITTEE REVIEW

 TRADING OF U.S. BIOSCIENCE STOCK SUSPENDED PENDING
 CONCLUSION OF FDA COMMITTEE REVIEW
 WEST CONSHOHOCKEN, Pa., Jan. 31 /PRNewswire/ -- U.S. Bioscience, Inc. (AMEX: UBS), a pharmaceutical company specializing in the development and commercialization of anticancer compounds, this afternoon announced that it has suspended the trading of its common shares pending the conclusion of a Food and Drug Administration Advisory Committee Review meeting taking place today.
 The company expects to issue a statement today after the FDA committee completes a review of U.S. Bioscience's drug Ethyol, a protective agent for use against the serious toxicities associated with chemotherapy using cisplatin and cyclophosphamide. products to increase the survival and quality of life for patients with cancer and allied diseases.
 -0- 1/31/92
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503; or Versaggi & Associates, 408-358-4162, or 408-395-1877, for U.S. Bioscience/
 (UBS) CO: U.S. Bioscience ST: California IN: MTC SU:


RM -- SJ003 -- 5732 01/31/92 15:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 31, 1992
Words:161
Previous Article:LL&E ROYALTY TRUST ANNOUNCES NO FEBRUARY DISTRIBUTION
Next Article:BANNER AEROSPACE ANNOUNCES THIRD QUARTER RESULTS
Topics:


Related Articles
FDA PANEL WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
TRADING IN EPITOPE HALTED PENDING CONCLUSION OF FDA BLOOD PRODUCTS ADVISORY COMMITTEE REVIEW OF PREMARKET APPROVAL APPLICATION
U.S. BIOSCIENCE AMENDS NEW DRUG APPLICATION FOR ETHYOL
U.S. BIOSCIENCE GETS CLEARANCE FOR NEUTREXIN; ADDITIONAL INFORMATION REQUESTED ON ETHYOL
ODAC WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL; U.S. BIOSCIENCE, INC. TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF ETHYOL
ICN SPECIAL COMMITTEE REPORTS TO THE BOARD

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters